Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Long-term data from QUILT-3.032 showed that NAI plus BCG shows sustained responses in BCG-unresponsive bladder cancer with 84 ...

Ramos, MD, PhD, discusses findings from cohort 4 of the phase 2 SunRISe-1 trial of TAR-200 in patients with high-risk, BCG-unresponsive NMIBC with papillary-only disease.

Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.

The first patient has been enrolled in a trial evaluating ClarityDX Prostate’s impact on early prostate cancer detection, ...

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for ...

Patients with metastatic colorectal cancer who received frontline immune checkpoint inhibitor therapy had positive OS rates ...

uGDB, utilizing next-generation sequencing to detect bladder cancer-associated mutations and DNA alterations, has previously shown associations with recurrence and therapy response.

With the clearance of an investigational new drug application from the FDA, a phase 1/2a study will evaluate VS-7375 in KRAS ...

Phase 1 trial of TGW101 in advanced solid tumors is enrolling to assess safety and pharmacokinetics and define the maximum ...